ContactsHome
Events > Next Event
Biotech & Pharma Innovation:
The Challenges, The Road Ahead and
What Other Industries Can Learn from the Life SciencesTuesday June 26th 7:30 am Sponsored by Wilmer Hale
Moderator: Carol Rozwell, Vice President and Distinguished Analyst, Life Sciences, Gartner, Inc.
Panelists: Bink Garrison, Senior Vice President and Catalyst, Vertex Pharmaceuticals
Markus Goebel, Managing Director, Novartis BioVenture Fund
Stephen Kellett, Product Line Manager, Academic Marketing, Affymetrix
Brock C. Reeve, Executive Director, Harvard Stem Cell Institute
Susan J. Ward, President and Co-founder, ThoughtLynx, Inc.Wilmer Hale
60 State Street
Boston MA
Driving DirectionsFew industries have changed as dramatically as the pharmaceutical and biotech industries. In a little over 50 years since the discovery of the structure of DNA, the pharmaceutical industry has transformed itself from an industry that had relied extensively on serendipitous discovery to one that uses systematic scientific approaches and an understanding of human and molecular biology to develop targeted treatments.
The reward for a successful new drug can be enormous, but the cost of failure can be devastating. The opportunities and the challenges have never been greater. Come and hear our distinguished panel discuss innovation in the biotech and pharmaceutical industries, and see what lessons your industry might learn from biotech and pharma.7:30 am - Continental Breakfast and Networking
8:00 to 9:30 am - Program$20 for PDMA members and students ($30 after June 20th -- $35 at the door)
$30 for non-members ($35 after June 20th -- $40 at the door)Speaker Bios
Carol Rozwell, Vice President and Distinguished Analyst, Life Sciences, Gartner, Inc.
Carol Rozwell is a Vice President and Distinguished Analyst in the Manufacturing Industry vertical at Gartner. Ms. Rozwell focuses on the Life Sciences sector (pharmaceutical, biotech and medical products companies) examining the impact of technology and standards on
business models, processes and channel relationships.Bink Garrison, Senior Vice President and Catalyst, Vertex Pharmaceuticals
Bink Garrison joined Vertex in December 2005 to help the company make the transition from a research-oriented organization to a full-scale drug company delivering innovative small-molecule pharmaceuticals to patients worldwide. From 2001 to 2005, he was the founder and President of Bink Inc., a strategic consulting firm. Prior to that, Mr. Garrison was the Chairman and CEO of Ingalls, Quinn & Johnson, one of New England's largest advertising agencies, for 18 years.Markus Goebel, Managing Director, Novartis BioVenture Fund
The Novartis Venture Fund invests in new business projects that show exemplary entrepreneurial and innovative spirit in future-oriented areas, especially in the fields of Health Sciences. Portfolio companies are typically university start-ups or spin-offs from Novartis that transfer highly innovative ideas and create economic impetus around the drug discovery and development process. Before joining the Fund as Managing Director in 2004, Dr. Goebel was the head of Pharma Corporate Mergers & Acquisitions and head of Nervous System BD&L Pharma. An M.D. by training and certified, among others, in Hematology/Oncology, he worked for Farmitalia Germany and later held several positions in R&D, Marketing and Strategy at Roche.Stephen Kellett, Product Line Manager, Academic Marketing, Affymetrix
Affymetrix is the worldwide leader in DNA microarrays, used in pharmaceutical and academic research. Prior to joining Affymetrix in 2002, Mr. Kellett led numerous cross-functional teams to bring products to market in the medical device, clinical diagnostics and life sciences industries, at companies that cover the size spectrum from pure start-ups working on their first product (Gamera Bioscience and DAS) to established, profitable mid-size organizations ($500M Ciba Corning Diagnostics) and large multinationals (>$5B Agilent Technologies and Philips Medical).Brock C. Reeve, Executive Director, Harvard Stem Cell Institute
The Harvard Stem Cell Institute is a scientific collaborative established to fulfill the promise of stem cell biology as the basis for cures and treatments for a wide range of chronic medial conditions. Mr. Reeve recently wrote, "The complexity of the science will require the community to collaborate; the importance of the ethical and social issues requires that collaboration to occur in a properly regulated framework; the immediacy and immensity of patient needs requires that we do so effectively and efficiently without reinventing the wheel."Susan J. Ward, President and Co-founder, ThoughtLynx, Inc.
Dr. Ward has served as an interim executive helping Biotechnology and pharmaceutically-oriented software companies transition technology into products since 2002. Prominent in pain research early in her career, Dr. Ward led the team that discovered new chemistries and the first known antagonists at cannabinoid receptors. Responsible for Wyeth UK and Global CNS drug discovery and subsequently for Wyeth's global Project and Portfolio Management in the 1990's, she oversaw the development of 30+ new and life cycle extension products. In 2000, Dr. Ward joined Millennium Pharmaceutical as a corporate officer and Senior VP for the company's Productivity and technology functions. Subsequently, she designed an integrated, award-winning infrastructure as EVP at Infinity Pharmaceuticals Inc. Currently, Dr. Ward is President and co-founder of ThoughtLynx, Inc.
